NJ026-0407

Peptidomics and Mass Spectrometry: Enabling the Discovery of Short Peptides as Novel Natural Products

Jong Suk Lee* and Jun Ho Shin

Bio Industry Department, Gyeonggido Business and Science Accelerator (GBSA), Suwon, 16229, South Korea

Correspondence to: Jong Suk Lee, leejs@gbsa.or.kr

Received: May 1, 2026; Revised: June 5, 2026; Accepted: June 5, 2026; Published: June 8, 2026

NATPRO J. 2026, 3, 17-22 

https://doi.org/10.23177/NJ026.0407 

Copyright ©  The Asian Society of Natural Products

Abstract

Food proteins are routinely exposed to gastrointestinal proteolysis, generating complex peptide mixtures that include both transient intermediates and biologically active sequences. While the nutritional role of proteins has long been recognized, the diversity and biological activity of peptides generated during digestion have remained largely unexplored due to analytical limitations. Recent advances in high-resolution mass spectrometry and peptidomics have made it possible to profile hydrolysis-derived peptides at scale with substantially improved depth and confidence. Short peptides represent a chemically diverse molecular space with potential applications as bioactive compounds. The theoretical diversity of peptide sequences increases exponentially (20ⁿ, where n = peptide length), far exceeding the structural space explored by conventional natural product discovery methods. Furthermore, peptides derived from dietary proteins are expected to exhibit favorable safety profiles due to their long history of human consumption. This perspective highlights the emerging paradigm of short peptide discovery through mass-spectrometry-based peptidomics and discusses its technological, industrial, and market implications for functional foods, pharmaceuticals, and cosmetic applications.

Keywords

short peptides, bioactive peptides, peptidomics, high-resolution mass spectrometry, natural product discovery, functional foods, peptide therapeutics, cosmetic peptides

1. Background

Proteins constitute a fundamental component of the human diet and have been consumed throughout human history as a major source of essential amino acids. During digestion, dietary proteins undergo enzymatic hydrolysis in the gastrointestinal tract, generating a wide range of peptides before being further degraded into free amino acids. This process is primarily mediated by proteolytic enzymes such as pepsin in the stomach and trypsin and chymotrypsin in the small intestine.

The biological significance of peptides as a molecular class has been recognized for well over a century. Beginning with the discovery of secretin by Bayliss and Starling in 1902, a succession of regulatory peptides including insulin, glucagon, oxytocin, vasopressin, and cholecystokinin (CCK) were systematically characterized throughout the twentieth century, establishing peptide hormones as indispensable mediators of endocrine and gastrointestinal physiology [1]. In parallel, venom-derived peptide toxins such as conotoxins from cone snails (Conus spp.) were recognized as a rich source of pharmacological probes with exquisite selectivity for ion channels and receptors [2]. Within this broader landscape, however, a specific subclass has remained analytically inaccessible until recently: short cryptic peptides embedded within dietary protein sequences and released upon gastrointestinal enzymatic digestion. Unlike endocrine peptide hormones, which are genetically encoded and present at physiologically detectable concentrations, digestion-derived bioactive peptides exist as latent sequences encrypted within precursor proteins and are generated stochastically during proteolysis. Their characterization was long impeded by the complexity of protein hydrolysate mixtures and the absence of sufficiently sensitive identification platforms. Accumulating evidence has now demonstrated that many such peptides possess significant biological activities, collectively referred to as bioactive peptides, including antihypertensive, antioxidant, antimicrobial, anti-inflammatory, and immunomodulatory effects [3,4]. The recent development of high-resolution mass spectrometry and peptidomics has provided, the analytical infrastructure needed to explore this cryptic peptide space systematically.

Despite their biological significance, systematic studies of digestion-derived peptides have been limited for decades due to analytical challenges. Protein hydrolysis produces complex peptide mixtures containing thousands of different peptide sequences with varying lengths and physicochemical properties. Conventional biochemical techniques lacked the resolution and sensitivity required to comprehensively identify and quantify such complex peptide populations.

The rapid development of high-resolution mass spectrometry (HRMS) and peptidomics technologies has fundamentally changed this landscape. Peptidomics refers to the large-scale analysis of peptide populations in biological samples, most commonly through LC-MS/MS workflows. Modern mass spectrometers such as Orbitrap and quadrupole-time-of-flight (Q-TOF) instruments provide high mass accuracy and fragmentation capabilities that enable reliable peptide sequencing even within highly complex mixtures [5, 6].

These technological advances have opened new opportunities for discovering bioactive peptides from widely available protein resources. Unlike traditional natural product discovery, which often relies on isolating small molecules from rare plants, microorganisms, or extreme environments, peptide discovery can be achieved through controlled hydrolysis of abundant proteins from food or biological sources.

2. Chemical Diversity and Discovery Potential of Short Peptides

One of the most compelling features of peptide-based discovery lies in the enormous combinatorial diversity of peptide sequences. Proteins are composed of 20 standard amino acids, and the theoretical diversity of peptides increases exponentially:

Chemical diversity = 20ⁿ (n = peptide length)

For example, an 8-mer peptide can theoretically generate more than 2.56 × 10¹⁰ possible sequence combinations. This combinatorial diversity far exceeds the structural diversity typically explored in conventional natural product screening programs.

This discovery strategy offers several practical advantages over classical natural-product workflows. First, peptides can be generated from abundant and inexpensive protein sources such as soy protein, milk proteins, fish proteins, and collagen, raw materials widely available and already utilized in food and nutraceutical industries [4]. Second, enzymatic hydrolysis methods can be easily scaled up for industrial production [7]. Third, bioactive peptides derived from food proteins with a long history of dietary consumption may benefit from favorable safety profiles relative to entirely novel chemical entities.

3. Peptidomics and Mass Spectrometry-Based Peptide Discovery

The emergence of LC-MS/MS-based peptidomics has provided a powerful analytical platform for exploring peptide diversity generated during protein hydrolysis. In a typical workflow, proteins from food or biological sources undergo enzymatic or chemical digestion to generate peptide mixtures. These mixtures are then separated by liquid chromatography and analyzed using tandem mass spectrometry. Mass spectrometry enables accurate determination of peptide masses and fragmentation patterns, allowing researchers to identify peptide sequences through database search algorithms, de novo sequencing approaches, or MS/MS spectral library matching.

In practice, this workflow proceeds through a series of analytically defined stages (Figure 1). Selected protein matrices, such as soy, milk, fish, and collagen, are subjected to controlled enzymatic hydrolysis using physiologically relevant proteases, typically pepsin under acidic conditions to simulate the gastric phase, followed by pancreatin at neutral pH (~7.0) to simulate the intestinal phase, in accordance with the standardized INFOGEST in vitro digestion protocol [8]. The resulting hydrolysate is then processed through sample preparation steps including solid-phase extraction (SPE) for desalting and cleanup, and molecular weight cut-off filtration to enrich for the short peptide fraction of interest [9]. Purified fractions are subsequently resolved by C18 or HILIC columns prior to online tandem mass spectrometric detection. Peptide sequence identification from acquired MS/MS spectra is achieved through three complementary strategies: database searching against protein sequence databases, de novo sequencing for sequences absent from existing databases, and spectral library matching against reference spectral collections. Identified sequences are then annotated for bioactivity using curated databases, enabling prioritization of candidates for downstream functional validation.

4. Industrial Applications

Short peptides identified through protein hydrolysis and peptidomics have already demonstrated significant commercial potential across multiple industrial sectors. Advances in analytical technologies and peptide purification methods have accelerated the translation of bioactive peptides from laboratory research to industrial applications, particularly in functional foods, pharmaceuticals, and cosmetic products.

4.1 Functional Foods and Nutraceuticals

Among the most successful applications of bioactive peptides are functional foods designed to improve cardiovascular health, metabolic regulation, and immune function. Several peptide-based ingredients derived from dietary proteins have already been commercialized and validated through clinical studies.

One of the most widely recognized examples is lactotripeptides (Val-Pro-Pro and Ile-Pro-Pro) derived from milk casein hydrolysis. These short peptides exhibit angiotensin-converting enzyme (ACE) inhibitory activity and have been demonstrated to reduce blood pressure in hypertensive individuals [17]. They are commercially marketed in fermented dairy products such as AmealPeptide® (Asahi Group Foods, Ltd., Japan), which has received approval as a Food for Specified Health Uses (FOSHU) product in Japan, one of the earliest regulatory validations of food-derived peptide ingredients.

Soy-derived bioactive peptides represent another well-established example. Enzymatic hydrolysis of soy protein generates peptides capable of modulating lipid metabolism and improving cardiovascular outcomes [18]. Commercial nutraceutical products containing soy peptide hydrolysates are marketed globally targeting metabolic syndrome and cardiovascular risk factors.

Marine protein hydrolysates have also gained considerable attention as sources of antihypertensive, antioxidant, and anti-inflammatory peptides [19]. Fish collagen peptide products are widely distributed as dietary supplements for joint health support and metabolic function, with multiple clinical studies supporting their efficacy [20].

4.2 Pharmaceutical Applications

Peptide therapeutics have emerged as a strategically important class of drugs due to their high specificity, potent biological activity, and relatively favorable safety profiles compared with small molecule drugs [21, 22].

A landmark example is Semaglutide (Ozempic®, Wegovy®; Novo Nordisk), a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the treatment of type 2 diabetes and obesity. Semaglutide represents one of the most commercially successful peptide-based drugs and underscores the therapeutic and commercial potential of engineered short peptide scaffolds derived from endogenous peptide hormones.

In the antiviral domain, Enfuvirtide, a 36-residue peptide targeting HIV gp41, demonstrates the utility of peptides as highly specific inhibitors of protein-protein interactions that are difficult to address with conventional small molecules. The antimicrobial peptide (AMP) space is equally active: short cationic AMPs derived from frog skin, insect hemolymph, and plant defensins are being actively investigated as alternatives to conventional antibiotics, with several candidates in clinical development [23, 24]. Critically, truncated synthetic analogs, often as short as 4–8 residues, retain substantial antimicrobial potency, significantly reducing production cost and immunogenic potential.

4.3 Cosmetic Applications

Short peptides are among the most widely used functional ingredients in the cosmetics industry, particularly in anti-aging and skin-repair formulations. Cosmetic peptides typically function by stimulating collagen synthesis, enhancing skin barrier function, or modulating cellular signaling pathways [25].

The most commercially prominent example is Matrixyl (Pal-Lys-Thr-Thr-Lys-Ser, palmitoyl pentapeptide-4; Sederma), a lipopeptide designed to stimulate extracellular matrix synthesis. Clinical studies have demonstrated statistically significant improvements in skin elasticity and wrinkle depth reduction in Matrixyl-containing formulations. Matrixyl is currently incorporated into hundreds of premium cosmetic products globally and has become a benchmark cosmetic peptide ingredient.

Another widely recognized cosmetic peptide is Argireline (acetyl hexapeptide-3), a synthetic peptide that inhibits the SNARE complex responsible for neurotransmitter release at neuromuscular junctions, producing a mild muscle-relaxing effect that reduces expression-driven wrinkle formation. Its topical mechanism of action has drawn parallels to injectable botulinum toxin, argireline is often marketed as a ‘topical Botox’-like ingredient, although its mechanism and clinical effect are not equivalent to botulinum toxin injections.

From a peptidomics perspective, the cosmetic peptide space remains relatively underexplored in terms of systematic discovery from natural protein hydrolysates. The application of LC-MS/MS-based peptide profiling to collagen, keratin, and silk protein hydrolysates presents an open opportunity for identifying novel cosmetic-function peptide candidates with natural origin claims, a marketing attribute of increasing consumer relevance.

4.4 Industrial Implications for Peptidomics-Based Discovery

The successful commercialization of peptide-based ingredients across these three industries highlights the transformative role that systematic peptide discovery platforms can play. Modern peptidomics technologies enable the identification of thousands of peptide sequences generated through enzymatic digestion in a single analytical run. Combining protein hydrolysis, LC-MS/MS analysis, and bioactivity prediction allows researchers to efficiently prioritize novel sequences with specific biological functions, a workflow far more scalable and cost-effective than classical natural product isolation.

As mass spectrometry technologies continue to evolve, particularly with the integration of ion mobility separation, real-time database-independent acquisition (DIA), and artificial intelligence-assisted de novo sequencing, peptide discovery is expected to transition from random screening toward targeted, data-driven pipelines. This paradigm shift may significantly accelerate the development of next-generation peptide-based ingredients across functional food, pharmaceutical, and cosmetic sectors.

5. Market Trends

The global market for bioactive peptides and peptide-derived materials has expanded substantially over the past decade, supported by demographic shifts toward aging populations, rising consumer interest in preventive nutrition, and advances in peptidomics and AI-assisted bioactivity prediction. Representative industry estimates suggest compound annual growth rates of 8–13% across functional food, pharmaceutical, and cosmetic sectors through 2024–2035 (Table 1). While these figures reflect genuine commercial momentum, they should be interpreted alongside persistent scientific and technical constraints that continue to limit broad translational success.

In the functional food and nutraceutical segment, antihypertensive lactotripeptides (Ameal S®), marine collagen peptides, and soy-derived ingredients represent the most commercially established categories [27, 29], with plant-derived peptides growing particularly rapidly (CAGR ~12%) driven by sustainability and clean-label positioning [28]. A critical limitation, however, is poor oral bioavailability: gastrointestinal proteolysis frequently degrades candidate sequences before systemic absorption, and robust clinical validation at physiologically relevant doses remains scarce for the majority of reported bioactive peptides.

Peptide therapeutics dominate in absolute value (USD 46.4 billion, 2024), exemplified by semaglutide (Ozempic®/Wegovy®, USD 13.89 billion in 2024 alone), which has established GLP-1 receptor agonists as the largest peptide drug class [32]. Nevertheless, short plasma half-lives, limited membrane permeability, and high solid-phase synthesis costs at scale have historically confined most approved peptide drugs to injectable formats, and overcoming these limitations remains an active area of formulation and chemical modification research [22].

In cosmetics, over 41% of luxury skincare launches in 2023 incorporated at least one functional peptide [30], and the AI-driven peptide discovery platform market is projected to grow from USD 3.11 billion to USD 10.5 billion by 2035 [31]. Asia-Pacific, led by South Korea, Japan, and China, represents the fastest-growing geographic frontier. Despite rapid commercialization, however, the clinical efficacy of most topically applied peptides remains difficult to substantiate owing to limited skin penetration and the absence of standardized bioactivity endpoints.

Collectively, sustained market growth will depend not only on discovery throughput enabled by modern peptidomics, but equally on resolving fundamental challenges in peptide stability, scalable production, delivery efficiency, and clinical validation.

6. Conclusion

Short peptides represent a highly promising platform for bioactive natural product discovery. The combination of protein hydrolysis, high-resolution mass spectrometry, and peptidomics enables systematic exploration of the peptide diversity generated from abundant protein resources. Given their enormous combinatorial diversity, scalability of production, favorable safety profiles, and demonstrated commercial precedents across functional foods, pharmaceuticals, and cosmetics, short peptides may provide an efficient and sustainable complement to traditional natural product discovery approaches.

Nevertheless, the discovery of naturally occurring short peptides remains analytically challenging. Their low molecular weight and limited fragmentation information can complicate confident sequence assignment and biological interpretation, particularly for novel peptides absent from existing databases. Furthermore, translating peptide identification into verified biological function remains a major bottleneck in current peptidomics workflows.

As analytical technologies, particularly mass spectrometry, continue to advance in sensitivity, throughput, and structural resolution, peptide-based discovery is poised to play an increasingly central role in the development of next-generation bioactive materials. Continued integration of high-resolution mass spectrometry, spectral library resources, artificial intelligence-assisted annotation, and experimental validation strategies will further enhance the reliability of short-peptide discovery. Cross-disciplinary collaboration between mass spectrometry specialists, natural product scientists, and material engineers will be essential to fully realize this potential.

References

1. Chen, C., et al. History of key regulatory peptide systems and perspectives for future research. J Neuroendocrinol. 2023, 35, e13251. https://doi.org/10.1111/jne.13251 

2. Lewis, R.J.; Garcia, M.L. Therapeutic potential of venom peptides. Nat Rev Drug Discov. 2003, 2, 790–802. https://doi.org/10.1038/nrd1197 

3. Korhonen, H.; Pihlanto, A. Bioactive peptides: production and functionality. Int Dairy J. 2006, 16, 945–960. https://doi.org/10.1016/j.idairyj.2006.10.012 

4. Udenigwe, C.C.; Aluko R.E. Food protein-derived bioactive peptides: production, processing, and potential health benefits. J Food Sci. 2012, 77, R11–R24. https://doi.org/10.1111/j.1750-3841.2012.02723.x 

5. Sánchez-Rivera, L., et al. Peptidomics for discovery, bioavailability and monitoring of dairy bioactive peptides. Food Res Int. 2014, 63, 170–181. https://doi.org/10.1016/j.foodres.2014.01.069 

6. Domon, B.; Aebersold, R. Mass spectrometry and protein analysis. Science, 2006, 312, 212–217. https://doi.org/10.1126/science.1124619 

7. Agyei, D.; Danquah, M.K. Industrial-scale manufacturing of pharmaceutical-grade bioactive peptides. Biotechnol Adv. 2011, 29, 272-277. https://doi.org/10.1016/j.biotechadv.2011.01.001 

8. Minekus, M., et al. A standardised static in vitro digestion method suitable for food - an international consensus. Food Funct. 2014, 5, 1113–1124. https://doi.org/10.1039/c3fo60702j 

9. Bougatef, A., et al. Purification and identification of novel antioxidant peptides from enzymatic hydrolysates of sardinelle (Sardinella aurita) by-products proteins. Food Chem. 2010, 118, 559–565. https://doi.org/10.1016/j.foodchem.2009.05.021 

10. Zubarev, R.A.; Mann, M. On the proper use of mass accuracy in proteomics. Mol Cell Proteomics. 2007, 6, 377–381. https://doi.org/10.1074/mcp.M600380-MCP200 

11. Seyfried, N.T., et al. MS Ana: improving sensitivity in peptide identification with spectral library search. J Proteome Res. 2023, 22, 462–470. https://doi.org/10.1021/acs.jproteome.2c00658 

12. Zhou, X.-X., et al. pDeep: Predicting MS/MS spectra of peptides with deep learning. Anal Chem. 2017, 89, 12690–12697. https://doi.org/10.1021/acs.analchem.7b02566 

13. Yilmaz, M., et al. Sequence-to-sequence translation from mass spectra to peptides with a transformer model. Nat Comm. 2024, 15, 6427. https://doi.org/10.1038/s41467-024-49731-x 

14. Nongonierma, A.B.; FitzGerald, R.J. Strategies for the discovery and identification of food protein-derived bioactive peptides. Trends Food Sci Technol. 2017, 69, 289–305. https://doi.org/10.1016/j.tifs.2017.03.003 

15. Minkiewicz, P.; Iwaniak A., Darewicz M. BIOPEP-UWM database of bioactive peptides: current opportunities. Int J Mol Sci. 2019, 20, 5978. https://doi.org/10.3390/ijms20235978

16. Qin, D.; Bo, W.; Zheng, X.; Hao, Y.; Li, B.; Zheng, J.; Liang, G. DFBP: a comprehensive database of food-derived bioactive peptides for peptidomics research. Bioinformatics, 2022, 38, 3275–3280. https://doi.org/10.1093/bioinformatics/btac323 

17. Sipola, M.; et al. Long-term intake of milk peptides attenuates development of hypertension in spontaneously hypertensive rats. J Physiol Pharmacol. 2002, 52, 745-754. http://www.jpp.krakow.pl/journal/archive/12_01/pdf/745_12_01_article.pdf

18. Nakamura, Y.; et al. Purification and characterization of angiotensin I-converting enzyme inhibitors from sour milk. J Dairy Sci. 1995, 78, 777–783. https://doi.org/10.3168/jds.S0022-0302(95)76689-9 

19. Harnedy, P.A.; FitzGerald, R.J. Bioactive peptides from marine processing waste and shellfish: a review. J Funct Foods. 2012, 4, 6–24. https://doi.org/10.1016/j.jff.2011.09.001 

20. Lafarga, T.; Hayes M. Bioactive peptides from meat muscle and by-products: generation, functionality and application as functional ingredients. Meat Sci. 2014, 98, 227–239. https://doi.org/10.1016/j.meatsci.2014.05.036 

21. Fosgerau, K.; Hoffmann, T. Peptide therapeutics: current status and future directions. Drug Discov Tod. 2015, 20, 122–128. https://doi.org/10.1016/j.drudis.2014.10.003 

22. Lau, J.L.; Dunn, M.K. Therapeutic peptides: historical perspectives, current development trends, and future directions. Bioorg Med Chem. 2018, 26, 2700–2707. https://doi.org/10.1016/j.bmc.2017.06.052 

23. Zasloff, M. Antimicrobial peptides of multicellular organisms. Nature, 2002, 415, 389–395. https://doi.org/10.1038/415389a 

24. Brogden, K.A. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nat Rev Microbiol. 2005, 3, 238–250. https://doi.org/10.1038/nrmicro1098 

25. Gorouhi, F.; Maibach, H.I. Role of topical peptides in preventing or treating aged skin. Int J of Cosmet Sci. 2009, 31, 327–345. https://doi.org/10.1111/j.1468-2494.2009.00490.x 

26. Bioactive Peptides Market – Industry Trends and Forecast to 2030. Data Bridge Market Research. 2023. https://www.databridgemarketresearch.com/reports/global-bioactive-peptides-market 

27. Collagen Peptides Market Size, Share, Growth and Industry Analysis, By Types (Fish collagen, Bovine collagen, Porcine Collagen), By Applications (Food Industrial, Health Products Industrial, Cosmetics Industrial, Others), Regional Insights and Forecast to 2035. Global Growth Insights. 2026. https://www.globalgrowthinsights.com/market-reports/collagen-peptides-market-112633 

28. Nandini, R. C. Plant Peptides Market. Future Market Insights. 2025. https://www.futuremarketinsights.com/reports/plant-peptides-market 

29. Peptide Therapeutics Market Size & Share 2025-2034. Global Market Insights. 2025. https://www.gminsights.com/industry-analysis/peptide-therapeutics-market 

30. Peptide Cosmetics Market Size, Share, Growth, and Industry Analysis, By Type (Serums, Moisturizers, Face Cream, Eyes Cream, Others), By Application (Supermarket, Specialty Retailers, Online Sales, Others), Regional Insights and Forecast to 2035. Market Growth Reports. 2026. https://www.marketgrowthreports.com/market-reports/peptide-cosmetics-market-104060 

31. Global AI-Driven Peptide Drug Discovery Platform Market Research Report. Wise Guy Reports. 2025. https://www.wiseguyreports.com/reports/ai-driven-peptide-drug-discovery-platform-market

32. Wenjing, X., et al. Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines. Signal Transduct Target The. 2025, 10, 74. https://doi.org/10.1038/s41392-024-02107-5